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KEPATUHAN TERHADAP PENGAMBILAN UBAT DALAM KALANGAN 
PESAKIT LUAR HIPERTENSI DI HOSPITAL BESAR PULAU PINANG,  
MALAYSIA 
 
ABSTRAK 
Secara umumnya, kepatuhan terhadap pengambilan ubat antihipertensi tidak 
didokumenkan kebanyakan di negara sedang membangun.  Di samping keberkesanan 
rawatan antihipertensi, kepatuhan terhadap pengambilan ubat adalah suboptimum dalam 
kalangan populasi hipertensi di Malaysia.  Kajian kohort retroprospektif ini bertujuan 
menilai kepatuhan terhadap pengambilan ubat  dan juga faktor yang mempengaruhinya.  
Seramai  380 pesakit hipertensi daripada klinik pesakit luar hipertensi di Hospital Besar 
Pulau Pinang  terlibat dalam kajian ini.  Skala lapor-sendiri Morisky mencatatkan 
bahawa 51.3% pesakit (n=195) mempunyai kepatuhan yang lemah terhadap 
pengambilan ubat antihipertensi yang dipreskribkan.  Temu bual berstruktur 
mencatatkan bahawa masalah lupa,  sokongan sosial yang lemah, kesan sampingan  
ubat, dan persepsi bahawa pengubatan jangka panjang mungkin akan menyebabkan 
ketagihan ubat, adalah faktor utama bagi kepatuhan yang lemah terhadap pengambilan 
ubat.  Pemodelan persamaan berstruktur (structural equation modelling, SEM), 
mengenal pasti peramal hipotesis multivariat bagi kepatuhan yang lemah terhadap 
pengambilan ubat, mendapati bahawa kekurangan displin diri, aversi terhadap ubat, dan 
sikap negatif terhadap ubat, secara umumnya merupakan 75% daripada faktor yang 
mempengaruhi kepatuhan terhadap pengambilan ubat.  ANOVA satu hala dan ujian t 
bebas daripada sampel bebas menunjukkan bahawa secara statistiknya tiada perbezaan 
yang signifikan (p>0.05 bagi semua) antara pesakit yang patuh dan tidak patuh, 
 XVI 
berhubung dengan pemboleh ubah demografi, termasuklah umur, gender, sejarah 
hipertensi keluarga, bangsa, tahap pendidikan dan pendapatan. Perkaitan yang signifikan 
ditemui dimana kepatuhan akan menjadi lebih baik jika mereka meningkatkan 
kekerapan dos harian lebih daripada satu regimen (p< 0.001).  Analisis regresi linear 
menunjukkan bahawa kepatuhan yang lemah secara signifikannya adalah peramal bebas 
daripada tekanan darah yang tidak terkawal.  Tekanan darah yang tidak dikawal juga 
adalah suatu peramal bebas yang signifikan bagi ketidaknormalan profil lipid dan paras 
glukos (p<0.05). Akhirnya, perkaitan yang signifikan ditemui dalam kohort di antara 
kepatuhan yang lemah dan peningkatan risiko kemasukan ke hospital (p<0.001).  
Berdasarkan keputusan ini, pengamal perubatan sepatutnya menyediakan pendidikan 
kepada pesakit tentang kepentingan pengambilan ubat antihipertensi dan menilai tahap 
sokongan sosial untuk mengoptimumkan kepatuhan mereka terhadap pengambilan ubat. 
Pengamal perubatan juga boleh menganjurkan program yang lebih sensitif bagi 
disesuaikan dengan keperluan setiap pesakit. Mereka  ini lebih berisiko terhadap 
penyakit koronari dan serebrovaskular dan juga kemasukan ke hospital  Oleh itu, 
kepatuhan terhadap pengambilan ubat dapat dianggap sebagai satu mediator yang 
penting antara amalan perubatan dan hasil keputusan pesakit. 
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ADHERENCE TO MEDICATION AMONG HYPERTENSIVE OUTPATIENTS 
IN THE PENANG GENERAL HOSPITAL, MALAYSIA 
 
ABSTRACT 
 Adherence to antihypertensive medications in general is not well documented in 
developing countries, and what is known is far from encouraging. Despite the 
effectiveness of antihypertensive treatment, medication adherence is often suboptimal in 
hypertensive Malaysian population. This retro-prospective cohort study aimed to assess 
the medication adherence, and factors affecting this. A cohort of 380 hypertensive 
patients was conveniently recruited from the outpatient hypertension clinic at Penang 
General Hospital, Malaysia. The Morisky self-report scale revealed that 51.3% patients 
(n=195) had poor adherence to prescribed antihypertensive medication. A Semi-
structured interview revealed forgetfulness due to a lack of symptoms; poor social 
support, medication side effects, and the perception that long-term medication may be 
addictive were principal factors of poor adherence to medication. The structural equation 
modelling (SEM), which identified the multivariate hypothesized predictors of poor 
adherence to medication, showed that a lack of self discipline, aversion towards 
medication, and a negative attitude towards medication in general negatively accounted 
for 75% of factors affecting medication adherence. The one-way ANOVA and 
independent t-tests of independent samples revealed no statistically significant 
differences (p>0.05 for all) between adherent and non-adherent patients with regards to 
demographic variables, including age, gender, family history of hypertension, race, 
educational level, and income. A significant association was found between patients had 
significantly better adherence if they had an increased daily frequency of doses than 
 XVIII 
once daily regimens (p<0.001). The linear regression analysis showed that poor 
medication adherence was a statistically significant (p<0.01) independent predictor of 
uncontrolled blood pressure. Uncontrolled blood pressure was also a significant 
independent predictor of abnormalities in the lipid profile and glucose levels (p<0.05). 
Finally, a significant association was found in this cohort between poor adherence to 
medication and an increased risk of hospital admission (p<0.001). Based on these 
results, healthcare providers should aim to enhance the awareness of patients about the 
importance of antihypertensive medications and assess the level of social support to 
optimize their adherence to medication. The healthcare provider may tailor more 
sensitive interventions programs to suit the unique needs of each patient. They are more 
at risk of coronary and cerebrovascular diseases and are more likely to experience 
hospital admission. Therefore, medication adherence is one of the crucial mediators 
between the aims of medical practice and the ultimate outcome for patients. 
 
 
 
 
 
 
 
 1 
CHAPTER 1 
INTRODUCTION 
 
1.1 Background of the Study 
The disease profile of the world is changing at a rapid rate. Chronic diseases, which 
include heart disease, stroke, cancer, hypertension, diabetes and mental illnesses, now 
account for 47% of the global burden of disease and 60% of all deaths (Jack, 2009). 
Based on World Health Organization (2003) eighty percent of these chronic disease 
deaths occur in the low and middle income countries, and 50% occur prematurely in 
people under the age of 70 years. This data disputes the long-held notion that chronic 
diseases mainly affect affluent countries and older individuals (World Health 
Organization, 2003). 
 
In Malaysia, chronic diseases are a major health problem, accounting for many of the 
most prevalent and costly illnesses. Such diseases account for 71% of all deaths and 
69% of the total burden of disease (Rampal et al., 2008). In fact, there is growing 
concern in the Malaysian Ministry of Health about the increasing prevalence of chronic 
diseases among its population (Lim & Morad, 2004). Healthcare professionals are 
considering the serious consequences of chronic illness that face the present generation, 
and plan for the burden that will be placed on the future generation unless appropriate 
action is taken (Ministry of Health Malaysia, 2006). Data from the Malaysian Ministry 
of Health Non-Communicable Disease Section (MOH-NCD, 2006) estimated that 
approximately 11.6 million of Malaysian adults aged between 25 and 64 years had at 
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least one risk factor for a chronic disease and only approximately 3% did not have any 
risk factors.  
 
Hypertension is one of the most common chronic diseases that affect the Malaysian 
population (Rampal et al., 2008). It is the main reason for clinic visits to physicians, as 
well as the most common outpatient diagnosis (Lim et al., 1992). Worldwide, the 
prevalence of hypertension was around 26% in 2000, and is projected to rise to 29% by 
2025 (Wu et al., 2009). According to the most recent data from the Ministry of Health 
Malaysia (2009), hypertension has been on the rise in Malaysia over the past 10 years 
and now affects an estimated 4.8 million Malaysians. This has also been reported by 
Rampal et al. (2008) in a recent national survey that sampled more than 16,000 
Malaysians, which showed that the prevalence of hypertension amongst those aged 30 
years and above had increased from 32.9% in 1996 to 40.5% in 2004, and 42.6% in 
2006.  
 
From observations on the current situation of hypertensive patients in Malaysia, Rampal 
reported in 2008 that the blood pressure (BP) of many treated hypertensive patients 
remained above the recommended target levels. This high failure rate of treatment has 
been ascribed largely to poor medication adherence. Martino et al. (2009) reported better 
control over BP levels among patients who take at least 80% of their medications 
compared with those who take less than 50% of their prescribed medications. The 
seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure identified poor medication adherence as the main 
cause for poor control of BP. 
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In fact, the concept of adherence to medication was first recognized as a major public 
health problem by Sackett et al. (1979) who reported that only about 50% of patients 
adhere to their prescribed medications. Recently, this point has also been supported by 
Vrijens et al. (2009), who reported that approximately half of the 4,783 patients who 
were prescribed 43 different antihypertensive drugs, including angiotensin II receptor 
blockers (n=2088), calcium channel blockers (n=937), angiotensin converting enzyme 
inhibitors (n=665), β-blockers (n=195), and diuretics (n=155), had stopped taking 
prescribed antihypertensive medication within one year.  
 
Evidently, poor adherence to medication is a serious healthcare concern and has 
provided challenges to healthcare providers. According to Vrijens et al. (2009) and Wu 
et al. (2009), adherence to treatment is a critical factor in the low rates of blood pressure 
control among people with hypertension. Gazmararian et al. (2010) stated that 
hypertension complication, such as cardiovascular and renal diseases is a major impact 
of poor adherence to antihypertensive medication. This point has been also expressed by 
Kim et al. (2010), who stated that non-adherence to antihypertensive treatment 
recommendations by patients remains a global problem, concluded that promoting 
patient medication adherence is a major clinical hurdle that is necessary to decrease the 
overall cardiovascular morbidity and mortality.  
 
The seriousness of poor adherence to treatment in Malaysia was highlighted in 2006 by 
Hassan et al. (2006) that 55.8% (n=240) of all classes of antihypertensive medication 
were not taken as directed in the Hospital University Sains Malaysia, Kelantan. The 
authors went on to argue that when medications are used incorrectly or not taken at all, 
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this represents a waste of the time, effort and expertise of the healthcare providers, 
which may impair the quality of life of patients, make their condition more difficult to 
treat, and cause further complications that creates further financial strain on the 
healthcare system.  
 
The information provided above enabled the formulation of six unresolved problems 
with regards to the adherence of patients to treatment for hypertension, which this study 
aimed to resolve. These six areas are outlined below. 
 
1.2 Research Problems 
This study identifies six problems as described below: 
 
1. Patients with well-controlled blood pressure represent only a small fraction of the 
hypertensive Malaysian population. 
2. To date, there has been a shortage of published academic and empirical research 
on medication adherence among hypertensive patients in Malaysia, most of the 
reviews of this subject were conducted in Europe or the USA. 
3. Most previous studies focused on non-medication adherence from the 
perspective of healthcare providers, and these tend to ignore the factors that 
influence the patients from their perspective. 
4. Inconclusive findings have been found in previous studies that investigated the 
relationship between adherence to antihypertensive medication and the frequency 
of dosages. 
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5. Few studies have explored the nature of the relationship between BP control and 
levels of plasma lipids and fasting blood glucose, and this gap has been identified 
as a further research. 
6. Few studies have shown the benefit of medication adherence with regard to a 
reduction in the risk of hospitalization for hypertensive patients, and this 
relationship is still unclear. 
 
1.3 Research Objectives 
The main objective of this thesis was to examine the adherence to medication among 
hypertensive outpatients who attend the Penang General Hospital. The specific research 
objectives, which were based on the research problems outlined in Section 1.2, were as 
follows: 
1. To identify patients with poor adherence to antihypertensive medication. 
2. To investigate the factors that influence adherence to antihypertensive medication. 
3. To examine the relationship between medication adherence and different daily 
dosing frequency among hypertensive patients.  
4. To examine the relationship between adherence to antihypertensive medication 
and the control of BP. 
5. To examine the relationship between BP control and lipid profile and glucose 
levels among hypertensive patients.  
6. To examine the relationship between medication adherence and its association 
with hospital admission rates among hypertensive patients. 
 
 
 6 
CHAPTER 2 
LITERATURE REVIEW 
 
The topics of (i) hypertension and (ii) medication adherence were reviewed and 
presented as follows:   
 
2.1  Hypertension  
2.1.1 Definition   
 
Hypertension is defined as a systolic blood pressure (SBP) of 140 mmHg or greater, 
and/or a diastolic blood pressure (DBP) of 90 mmHg or greater (The Seventh Report of 
the Joint National Committee [JNC 7], 2003).  
 
The Seventh Report of the Joint National Committee (2003) report has introduced a new 
classification that includes four categories: normal BP (SBP <120 mmHg and DBP <90 
mmHg); pre-hypertension (SBP between 120 and 139 mmHg and/or DBP between 80 
and 89 mmHg); stage I (SBP between 140 and 159 mmHg and/or DBP between 90 and 
99 mmHg); and stage II (SBP >160 mmHg and/or DBP >110 mmHg). 
 
2.1.2 Epidemiology 
Hypertension is a key contributing cause for at least one third of the premature deaths 
that are due to heart attacks and even a higher proportion of premature deaths due to 
stroke (Kandiah et al., 1980). The Framingham Heart Study on the role of BP in the 
development of congestive heart failure showed that the dominant etiological precursor 
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was hypertension in 75% of cases (Kannel, 1986). There is increasing evidence that the 
optimal control of hypertension would reduce the incidence of coronary heart disease 
and cerebrovascular accidents. 
 
Unfortunately, as Malaysia approaches attaining developed nation status by 2020, the 
prevalence of chronic lifestyle diseases, such as hypertension, is likely to increase. In 
fact, periodic national surveys have shown a steady increase over recent years in the 
prevalence of hypertension (Minister of Health Malaysia, 2009). The latest National 
Health and Morbidity Survey in 2006 showed that the prevalence of essential 
hypertension among Malaysian adults aged 30-years-old and above was 43%, which had 
increased from 33% recorded 10 years ago (Rampal et al., 2008). Moreover, among 
patients with hypertension who were on drug treatment, only 26% of them had achieved 
their target blood pressure (Ministry of Health Malaysia, 2006). This finding is 
consistent with a separate survey conducted by the Institute for Health Management of 
the Health Ministry with regards to the outpatient management of hypertension in 
government-funded clinics (Ministry of Health Malaysia, 2009). That survey found that 
only 28.5% of patients achieved the target blood pressure while receiving anti-
hypertensive medication. 
 
The estimated figure of essential hypertension worldwide is a staggering one billion 
individuals (Chobanian et al., 2003). It is now estimated that there are 4.8 million 
individuals with essential hypertension in Malaysia. It is also alarming to note that 
nearly two thirds of individuals with hypertension in Malaysia were unaware of their 
diagnosis; although there has been an increase in the proportion of individuals who 
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received treatment among those diagnosed, the rate of controlled hypertension remains 
poor (Ministry of Health Malaysia, 2009). Since the proportion of hypertensive people 
will increase dramatically worldwide in the years to come, the prevention, detection, 
treatment and control of this condition has become a major public health priority. 
 
2.1.3 Types of hypertension 
Primary hypertension, which is also termed essential or idiopathic hypertension, 
accounts for between 90 and 95% of the all cases of hypertension. This chronic elevation 
in BP occurs in the absence of evidence of any other disease processes (Chobanian et al., 
2003). 
 
Secondary hypertension, which accounts for the other 5% to 10% of cases of 
hypertension, is caused by other pathological states. These causes include renal diseases 
(for example, acute glomerulonephritis, renal tumors), endocrine disorders (for example, 
primary aldosteronism), vascular disorders, pregnancy related disease, such as pre-
eclampsia, and drug-related disorders (for example oral contraceptive pills, steroids, and 
cyclosporin; Chobanian et al., 2003). 
 
2.1.4 Signs and symptoms 
In most cases, hypertension causes no symptoms. However, if the BP levels are very 
high, headaches, epistaxis, tinnitus, depression and dizziness can occur, but these 
complaints are relatively nonspecific (Mulatero et al., 2009; Kearney et al., 2005; Oparil 
et al., 2003). 
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2.1.5 Complications of hypertension 
The complications of hypertension are a consequence of the degenerative vascular 
changes that affect several organs, such as the heart, brain, and kidneys. Patients who 
have uncontrolled hypertension and are non-adherent to anti-hypertensive medications 
may proceed to develop the following complications (JNC, 2003): 
 
i) Heart failure, myocardial ischemia, and myocardial infarction are common 
complications of hypertension (Uren & Rutherford, 2010). Hypertension precedes left 
ventricular failure due to its increased work because of the increased resistance in the 
systemic vascular system. In the first stage of this process, the left ventricle becomes 
hypertrophic. In the longer term, the myocardium loses contractility, which causes a 
gradual expansion and loss of efficiency of the left ventricle. The myocardium will 
eventually become dilated and congestive heart failure occurs with a high associated 
mortality and morbidity (Beulens et al., 2007). 
 
ii) Chronic hypertension can lead to the formation of aneurysms within the arterial walls 
in the brain, which causes the artery to lose its contractility (Mancia et al., 2008). When 
blood pressure increases further, the aneurysm may rupture, resulting in intracerebral 
hemorrhage or stroke. There is a high incidence of stroke in individuals with essential 
hypertension in Western countries, with high rates of morbidity and even mortality 
depending on the size and location of the stroke unless patients receive immediate 
specialized treatment (Agarwal et al., 2008). 
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iii) The rate of onset of renal failure in a hypertensive individual is directly proportional 
to the level of BP and the rate that the glomerular filtration rate (GFR) deteriorates (Uren 
& Rutherford, 2010). The GFR commonly declines by 4 and 8 ml/min per year if the 
SBP remains uncontrolled (Alan, 2010). Uncontrolled hypertension can induce 
arteriosclerosis in multiple vessels, including the renal artery, which leads to renal 
failure and uremia. The retention of urine is common urological problem and highly 
toxic due to accumulation of urine in the bladder. The increase in pressure in the bladder 
can also prevent urine entering from the ureters or even cause urine to pass back up the 
ureters and get into the kidneys, causing hydronephrosis, possibly pyonephrosis, kidney 
failure, sepsis, and if remain untreated may result in impaired consciousness and death 
(Beulens et al., 2007). 
 
iv) Vascular complications of hypertension include embolism, thrombosis and 
hemorrhage. The presence of atherosclerotic plaques leads to ineffective blood 
circulation and a reduction in the blood supply to the high-risk target organs, which 
include the heart, brain and kidney. Eventually, these result in organ dysfunction, such 
as in the development of exertional angina, memory impairment and renal dysfunction 
(Uren & Rutherford, 2010).  
 
v) The risk of blindness increases due to the thickening of the walls of the retinal 
arteries, which can lead to hemorrhage. Blood is toxic to the optic nerve, and vision 
becomes gradually more impaired (Alan, 2010). 
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2.1.6 Management of hypertension 
The goal of the management of hypertension is to reduce cardiovascular, 
cerebrovascular, renal and optical morbidity and mortality. High BP can be controlled 
within the safe range of normal, as stated in by Section 2.1.3, by non-pharmacological 
management alone or in combination with pharmacological management.  
 
2.1.6.1   Non-pharmacological management 
Based on the report by the JNC-7 in 2003, non-pharmacological management plays an 
important role in the treatment of hypertension. It involves lifestyle modifications, such 
as dietary adaptations, exercise, and smoking cessation, amongst others that will be 
discussed below (Malaysian Index of Medical Specialties, 2007).These strategies should 
form the basis for the initial advice given to most patients with primary hypertension. 
Such measures may comprise the only treatment that is necessary in Stage 1 of 
hypertension and can reduce blood pressure by an average of 10 mmHg (SBP) and 8 
mmHg (DBP) (Mancia et al., 2008). 
 
Non-pharmacological management strategies:  
a) Weight reduction  
Overweight (body mass index > 25 kg/m 2) has been seen in epidemiologic studies to be 
an important risk factor for higher blood pressure, and there seems to be a linear relation 
between body weight and blood pressure. Clinical trials have shown that weight loss, 
especially when combined with dietary sodium restriction, lowers blood pressure in 
hypertensive and also in normotensive patients (Morgan, 2000).   
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The Hypertension Prevention Trial showed that a 4% reduction in body weight over 3 
years was associated with a 2.4 mmHg reduction in systolic and a 1.8 mmHg reduction 
in diastolic blood pressures (Morgan, 2000). It is therefore important that all patients be 
advised to maintain weight near optimal by reducing calorie intake and increasing 
physical activity.  
 
b) Avoidance of excessive alcohol intake  
Alcohol has an acute effect in elevating BP. The standard advice is to restrict the intake 
of alcohol to no more than 21 units for men and 14 units for women per week (Mancia et 
al., 2008). Hypertensive patients who are heavy drinkers are more likely to be resistant 
to drug treatment. The only way to reduce BP effectively in this scenario is by planning 
a reduction or cessation strategy for their alcohol intake (Malaysian Index of Medical 
Specialties, 2007). 
 
c) Sodium intake  
Dietary salt intake has a linear association with blood pressure. Reduced sodium intake 
to approximately 100 mmol/ day can prevent hypertension, can facilitate blood pressure 
control in patients on medication and can potentially prevent cardiovascular events in 
overweight individuals (Uren & Rutherford, 2010). The Trials of Hypertension 
Prevention, showed that sodium reduction, alone or combined with weight reduction, 
can reduce the incidence of hypertension by approximately 20%. The data from these 
trials led to current recommendations to limit salt intake to 6 g/day, (100 mmol of 
sodium or 2.4 g per day) (Morgan, 2000). 
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To reduce salt intake, individuals should consume foods low in salt and limit the amount 
of salt added to food. Food rich in salt, like pickles, processed foods, chips and chutneys, 
should be avoided. 
 
d) Regular physical exercise  
Increasing aerobic physical activity such as brisk walking, jogging, swimming or 
bicycling has been shown to lower BP (Morgan, 2000). Significantly; this reduction is 
independent of any concomitant weight loss. A meta-analysis of 54 randomized 
controlled trials showed a net reduction of 3.8 mmHg in systolic and 2.6 mmHg in 
diastolic BP in individuals performing aerobic exercises, compared to controls (Agarwal 
et al., 2008). General advice on cardiovascular health would be for “milder” exercise, 
such as brisk walking for 30 – 60 minutes at least three times a week. 
 
e) Cessation of smoking  
This is important in the overall management of the patients with hypertension in 
reducing cardiovascular risk. Smoking can also acutely increase BP (Malaysian Index of 
Medical Specialties, 2007). Smoking injures blood vessel walls and speeds up the 
process of hardening of the arteries atherosclerosis (Morgan, 2000). Moreover, the 
nicotine in cigarettes and other tobacco products raise blood pressure by constricting the 
blood vessels. This occurs because the oxygen in blood decreases and because nicotine 
directly stimulates the production of a hormone, epinephrine (adrenaline), in the adrenal 
gland. Epinephrine raises blood pressure by constricting blood vessels. After tobacco use 
raises blood pressure, smoker at risk of all the medical consequences of high blood 
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pressure, not to mention diseases associated with smoking, such as mouth and lung 
cancer (Malaysian Index of Medical Specialties, 2007). 
 
f)  Healthy eating 
Appel et al. (1997) demonstrated that a diet rich in fruits, vegetables and dairy products 
with reduced saturated and total fat content can lower BP significantly (11/6 mmHg in 
hypertensive patients and 4/2 mmHg in patients with a BP in the higher end of the 
normal range). This type of diet also has a beneficial effect on overall cardiovascular 
health (Malaysian Index of Medical Specialties, 2007). 
 
2.1.6.2   Pharmacological management 
When pharmacological management is instituted, antihypertensive drugs will be given in 
a sequence, depending on the response of the patient. Firstly, if there is no indication of 
a specific drug intervention, such as the presence of heart failure, diabetes mellitus, and 
renal disease, diuretic drugs are the first choice of drug as a monotherapy for stage I 
hypertensive patients. Combined antihypertensive drugs are recommended for stage II 
hypertensive patients; diuretic drugs in combination with other drug groups are 
habitually used as the first choice of drug. Secondly, if the first drug group is not 
effective for adequate BP control to reach a normal level, other antihypertensive drug 
groups or adding a higher dosage of diuretic should be added, provided that the patient 
can tolerate the potential side effects (Chobanian et al., 2003). The major classes of 
antihypertensive agents are as follows:  
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Diuretics   
Diuretics are among the most commonly used drugs in the management of hypertension. 
They act by diminishing sodium chloride reabsorption at different sites in the nephron, 
thereby increasing urinary sodium chloride and water losses. The diuretics are generally 
divided into three major classes, which are distinguished by the site at which they impair 
sodium reabsorption:  
1. Loop diuretics act in the thick ascending limb of the loop of Henle. 
2. Thiazide-type diuretics in the distal tubule and connecting segment (and perhaps 
the early cortical collecting tubule). 
3. Potassium-sparing diuretics in the aldosterone-sensitive principal cells in the 
cortical collecting tubule. 
 
Diuretics are usually used as an initial therapy. They also enhance the efficacy of other 
classes of antihypertensive drugs when used in combination with other medications. In 
the elderly patient who has no comorbid conditions, diuretics are the drugs of choice in 
the treatment of combined systolic and diastolic hypertension and isolated systolic 
hypertension. The use of diuretics has been shown to reduce the incidence of fatal and 
non-fatal strokes as well as cardiovascular morbidity and mortality (Davis et al., 2003). 
 
Adverse effects with use of diuretics are uncommon, unless high doses are used. 
Adverse effects include increased serum cholesterol, glucose and uric acid; decreased 
potassium, sodium and magnesium levels and erectile dysfunction. Serum electrolytes, 
in particular potassium, should be closely monitored (Chobanian et al., 2003). However, 
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diuretics should be used with care in patients with gout, as they may precipitate an acute 
attack because diuretics are supposed to have a direct effect on ion exchanger proteins at 
the proximal tubule lumen membrane in the kidney which enhances the urate 
reabsorption, resulting in higher blood levels of uric acid. These higher levels reach a 
supersaturation level, and this is followed by shedding and precipitation of urate crystals 
into joints or subcutaneous tissues. The joint precipitation activates cellular signal 
transducers and induces inflammatory mediators, resulting in gouty synovitis  (Davis et 
al., 2003). 
 
Thiazide diuretics are cheap and are one of the most widely-used antihypertensive 
agents. When used in patients with essential hypertension and relatively normal renal 
function, thiazides are more potent than loop diuretics. However, in patients with renal 
insufficiency with a serum creatinine ≥200 µmol/L, thiazides are less effective and loop 
diuretics should be used instead (Vasavada et al., 2003). 
 
Potassium-sparing diuretics may cause hyperkalemia if given together with angiotensin 
converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), or are 
given in patients with underlying renal insufficiency. Aldosterone antagonists and 
potassium-sparing diuretics should be avoided in patients with serum potassium levels 
greater than 5.0 mmol/L (Chobanian et al., 2003). 
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Table 2.1: Diuretics commonly used for the treatment of hypertension in Malaysia 
 
Diuretics Starting  dose Maximum daily dose 
Chlorothiazide 250 mg od 500 mg od 
Hydrochlorothiazide 25 mg od 200 mg od 
Chlorthalidone 50 mg od 200 mg od 
Amiloride/hydrochlorothiazide 5 mg/50 mg 1 tablet od 4 tablet od 
Indapamide SR 1.5 mg od 1.5 mg od 
Indapamide 2.5 mg od 2.5 mg od 
Triamterene / hydrochlorothiazide 50 mg/25mg 1 tablet bd 2 tablets bd 
Source: Malaysian Index of Medical Specialties (2007) 
 
 
β-blockers  
Beta blockers, also known as beta-adrenergic blocking agents, are drugs that block 
norepinephrine and epinephrine (adrenaline) from binding to beta receptors on nerves. 
There are three types of beta receptors and they control several functions based on their 
location in the body.  
· Beta-1 (β1) receptors are located in the heart, eye, and kidneys;  
· Beta (β2) receptors are found in the lungs, gastrointestinal tract, liver, uterus, 
blood vessels, and skeletal muscle; and  
· Beta (β3) receptors are located in fat cells.  
 
β-blockers have long been established agents for the treatment of hypertension. They are 
particularly useful in hypertensive patients with exertional angina, tachyarrhythmias or 
previous myocardial infarction where they have been shown to reduce cardiovascular 
morbidity and mortality (Zhang et al., 2006).  
 
Certain β-blockers, such as bisoprolol and long-acting metoprolol have been shown to be 
beneficial in patients with heart failure. β-blockers are contraindicated in patients with 
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obstructive airways disease, severe peripheral vascular disease and second and third 
degree heart block (Zhang et al., 2006). 
 
They are generally well-tolerated medications. Adverse effects that have been reported 
include dyslipidemia, the masking of hypoglycemia, and an increased incidence of new-
onset diabetes mellitus, erectile dysfunction, nightmares and cold extremities. 
 
Table 2.2: Beta-blockers commonly used for the treatment of hypertension in 
Malaysia  
 
Beta-blockers Starting  dose Maximum daily dose 
Acebutolol 200 mg bd 400 mg bd 
Atenolol 50 mg od 100 mg od 
Betaxolol 10 mg od 40 mg od 
Bisoprolol 5 mg od 10 mg od 
Metoprolol 50 mg bd 200 mg bd 
Propranolol 40 mg bd 320 mg bd 
Source: Malaysian Index of Medical Specialties (2007) 
 
Calcium channel blockers (CCBs) 
Calcium channel antagonists block the inward movement of calcium by binding to the 
L-type calcium channels in the heart and in smooth muscle of the peripheral vasculature. 
CCB’s dilate coronary arteries and peripheral arterioles, but not veins. They also 
decrease cardiac contractility (negative inotropic effect), automaticity at the SA node 
and conduction at the AV node. Dilation of the coronary arteries increases myocardial 
oxigen supply 
 
Long-acting CCBs have been shown to be safe and effective in lowering blood pressure, 
both as first-line agents and in combination with other classes of antihypertensive drugs 
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(Julius et al., 2004).There are three major classes of CCBs (phenylalkylamines, 
dihydropyridines and benzothiazepines), which have different pharmacological 
characteristics and all are effective in lowering BP (Malaysian Index of Medical 
Specialties, 2007). With only a few exceptions, they have no undesirable metabolic 
effects, and their side effect profile in the management of hypertension is good. 
Dihydropyridines are particularly effective in reducing isolated systolic hypertension 
(Chobanian et al., 2003). They are also effective in reducing cerebrovascular events by 
10% compared with other active therapies (Zhang et al., 2006). 
 
A study by Julius et al. (2004) revealed the potentially harmful effects of short-acting 
calcium channel blockers, especially of the dihydropyridine type, in patients with 
coronary heart disease. Some have argued that long-acting calcium channel blockers are 
safer.  
 
The use of sublingual nifedipine is also discouraged. Its adverse effects include initial 
tachycardia, headache, flushing, constipation and ankle edema. Unlike other CCBs, 
verapamil may reduce the heart rate of the patient and care should be taken when used in 
combination with beta-blockers (Zhang et al., 2006). 
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Table 2.3: CCBs commonly used for the treatment of hypertension in Malaysia  
 
CCBs Starting  dose Maximum daily dose 
Amlodipine 5 mg od 10 mg od 
Diltiazem 30 mg tds 60 mg tds 
Diltiazem SR 90 mg bd 90 mg bd 
Diltiazem R 100-200 mg od 100-200 mg od 
Felodipine 2.5 mg od 10 mg od 
Isradipine 1.5 mg bd 2.5 mg bd 
Lacidipine 2 mg od 6 mg od 
Lercanidipine 10 mg od 20 mg od 
Nicardipine 10 mg tds 20 mg tds 
Nifedipine 10 mg tds 30 mg tds 
Nifedipine SR 30 mg od 120 mg od 
Verapamil 80 mg bd 240 mg tds 
Verapamil CR 200 mg od 200 mg bd 
Source: Malaysian Index of Medical Specialties (2007) 
 
 
Angiotensin-converting enzyme inhibitors (ACEIs)  
Angiotensin II is a very potent chemical that causes the muscles surrounding blood 
vessels to contract, thereby narrowing the vessels. The narrowing of the vessels 
increases the pressure within the vessels causing high blood pressure (hypertension). 
Angiotensin II is formed from angiotensin I in the blood by the enzyme angiotensin 
converting enzyme (ACE). ACE inhibitors are medications that slow (inhibit) the 
activity of the enzyme ACE, which decreases the production of angiotensin II. As a 
result, the blood vessels enlarge or dilate, and blood pressure is reduced. This lower 
blood pressure makes it easier for the heart to pump blood and can improve the function 
of a failing heart. 
 
ACEIs are generally well-tolerated and do not have adverse effects on the metabolism of 
lipid and glucose. Their safety profile is good. ACEIs have been shown to reduce 
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mortality and morbidity in patients with congestive heart failure and in patients who 
have suffered a myocardial infarction with reduced left ventricular ejection fraction 
(Malaysian Index of Medical Specialties, 2007).  
 
In the patient with diabetes, ACEIs have been shown to reduce the moratlity rate due to 
cardiovascular complications (Jafar et al., 2003). In addition, they have been shown to 
prevent the onset of microalbuminuria, reduce proteinuria and delay the progression of 
renal disease (Heeg et al., 1989). ACEIs have also been shown to reduce proteinuria and 
delay the progression of non-diabetic renal disease (Klahr et al., 1994). 
 
In patients with established vascular disease but with normal left ventricular function, 
ACEIs reduce mortality, myocardial infarction, stroke and new onset congestive heart 
failure (Malaysian Index of Medical Specialties, 2007). These benefits are independent 
of their effects on left ventricular function and blood pressure. 
 
The adverse effects of ACEIs include cough and, rarely, angioedema. In patients with 
renovascular disease or renal impairment, a deterioration in renal function may occur. 
Serum creatinine should be checked before the initiation of ACEI therapy and repeated 
within one to two weeks after initiation. Any increase in creatinine should be confirmed 
immediately and monitored. If there is a rise of serum creatinine of more than 30% from 
the baseline level within two months, the ACEI should be stopped (Jafar et al., 2003). 
ACEIs may increase fetal and neonatal mortality and, therefore, are contraindicated in 
pregnancy and in those planning pregnancy.  
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Table 2.4: ACEIs commonly used for the treatment of hypertension in Malaysia  
 
ACEIs Starting  dose Maximum daily dose 
Captopril 25 mg bd 50 mg tds 
Enalapril 2.5 mg od 20 mg bd 
Fosinopril 10 mg od 40 mg od 
Lisinopril 5 mg od 80 mg od 
Perindopril 2 mg od 8 mg od 
Quinapril 2.5 mg od 40 mg bd 
Ramipril 2.5 mg od 10 mg od 
Imidapril 2.5 mg od 10 mg od 
Source: Malaysian Index of Medical Specialties (2007) 
 
 
Angiotensin receptor blockers (ARBs) 
ARBs are receptor antagonists that block type 1 angiotensin II (AT1) receptors on 
bloods vessels and other tissues such as the heart. These receptors are coupled to the Gq-
protein and IP3 signal transduction pathway that stimulates vascular smooth muscle 
contraction. 
 
 Unlike ACEIs, the side effect of a persistently dry cough is less of a problem as the 
lung-specific ACE is not inhibited as well. As such, ARBs are recommended in patients 
who are intolerant to ACEI treatment. However, as with ACEIs, they are contraindicated 
in pregnancy and patients who have bilateral renal artery stenosis to avoid increasing the 
risk of acute renal failure due to renal artery contraction. ARBs are effective in 
preventing the progression of diabetic nephropathy (Brenner et al., 2001) and may 
reduce the incidence of major cardiac events in patients with heart failure (McMurray et 
al., 2003), hypertensive left ventricular hypertrophy (LVH; Dahlof et al., 2002), and 
heart failure (Yusuf et al., 2003). 
 
 23 
Table 2.5: ARBs commonly used for the treatment of hypertension in Malaysia  
 
ARBs Starting  dose Maximum daily dose 
Candesartan 8 mg od 16 mg od 
Irbesartan 150 mg od 300 mg od 
Losartan 50 mg od 100 mg od 
Telmisartan 20 mg od 80 mg od 
Valsartan 80 mg od 160 mg od 
Olmesartan 20 mg od 40 mg od 
Source: Malaysian Index of Medical Specialties (2007) 
 
Miscellaneous drugs 
(i) The a-blockers and the combined a-b blockers 
a-blockers lower BP by mediating a reduction in peripheral vascular resistance. They 
also reduce prostatic and urethral smooth muscle tone and provide symptomatic relief 
for patients with early benign prostatic hypertrophy (BPH). They are the logical choice 
for the treatment of hypertensive patients with BPH. The use of non-specific a-blockers, 
such as phentolamine and phenoxybenzamine, has been restricted to the treatment of 
pheochromocytoma. 
 
a-blockers have favorable effects on lipid metabolism. However, postural hypotension is 
a well-described side effect; especially at the initiation of therapy (Gillenwater et al., 
1995). 
 
Table 2.6: a- blockers commonly used for the treatment of hypertension 
 
a- blockers  Starting  dose Maximum daily 
dose 
Doxazosin 1 mg od 16 mg od 
Prazosin 0.5 mg bd 10 mg bd 
Terazosin 1 mg od 5 mg od 
Source: Malaysian Index of Medical Specialties (2007) 
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Alpha-beta blockers belong to a larger class of medicines called adrenergic inhibitors. 
They combine the effects of two types of medicines. They behave like alpha blocker 
medicines when they affect special receptor cells in the smooth muscles of blood 
vessels. This action stops cells from receiving chemicals called catecholamines. These 
chemicals narrow arteries. This makes blood pressure go up. When these chemicals are 
blocked, blood vessels can relax. This in turn allows blood to flow more easily, resulting 
in lower blood pressure. 
 
Combined a-b blockers that are commonly used for the treatment of hypertension in 
Malaysia include labetalol and carvedilol. Labetalol has been in use for over 20 years 
and is known to be safe for use during pregnancy. The intravenous formulation is also 
useful in hypertensive emergencies, including pre-eclampsia and eclampsia (Vigil et al., 
2006). 
 
Carvedilol has been shown to be effective in the control of primary hypertension and 
also improves the mortality and morbidity rates of patients with heart failure (Bakris et 
al., 2004). In addition, it has no adverse effects on insulin resistance and lipid 
metabolism (Balenis et al., 2004). However, its safety in pregnancy has not been 
established. 
 
Table 2.7: a ‚ b -blockers commonly used for the treatment of hypertension  
 
a ‚ b - blockers Starting  dose Maximum daily dose 
Labetalol* 100 mg bd 800 mg tds 
Carvedilol 12.5 mg od 50 mg od 
* In the elderly, start with 50 mg bd 
Source: Malaysian Index of Medical Specialties (2007) 
